Trial shows no difference in pain scores and quality of life for men with mCRPC receiving Olaparib plus Abiraterone versus placebo, indicating potential clinical benefits.
In PROpel, there were no differences in HRQoL or pain scores reported by patients with mCRPC receiving olaparib + abiraterone versus placebo + abiraterone, suggesting that patients can derive a clinical benefit from olaparib + abiraterone while maintaining similar HRQoL in comparison with current standard-of-care treatment. The PROpel trial is registered on ClinicalTrials.gov as NCT03732820.
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: